Citigroup Inc. Sells 73,833 Shares of Natera, Inc. $NTRA

Citigroup Inc. trimmed its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 45.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 88,732 shares of the medical research company’s stock after selling 73,833 shares during the period. Citigroup Inc. owned about 0.06% of Natera worth $14,283,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in the business. JPMorgan Chase & Co. increased its holdings in shares of Natera by 9.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock valued at $1,871,914,000 after acquiring an additional 1,003,129 shares during the period. Rakuten Investment Management Inc. purchased a new stake in shares of Natera during the 3rd quarter worth $34,096,000. SWS Partners lifted its stake in shares of Natera by 11.8% during the 3rd quarter. SWS Partners now owns 47,037 shares of the medical research company’s stock worth $7,572,000 after purchasing an additional 4,980 shares during the last quarter. New York State Common Retirement Fund boosted its position in Natera by 63.2% during the third quarter. New York State Common Retirement Fund now owns 148,247 shares of the medical research company’s stock valued at $23,863,000 after purchasing an additional 57,400 shares in the last quarter. Finally, Vontobel Holding Ltd. grew its stake in Natera by 192.5% in the third quarter. Vontobel Holding Ltd. now owns 8,531 shares of the medical research company’s stock valued at $1,373,000 after purchasing an additional 5,614 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

More Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Quarterly beat — Natera reported Q4 revenue of $665.5M and GAAP EPS of $0.35, well ahead of street estimates (revenue ~$600.7M, EPS loss consensus). The beat supports near-term growth expectations and underpins the stock’s recent strength. Natera Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Favorable clinical data — New Signatera MRD data presented at ASCO GU highlight potential utility across genitourinary cancers (including bladder preservation), which may expand clinical adoption and long-term revenue for Natera’s oncology franchise. Signatera MRD Data at ASCO GU
• Positive Sentiment: Trial results — Natera reported results from the SINERGY trial, another clinical datapoint that could support commercial adoption of its assays. Natera Announces Results From the SINERGY Trial
• Positive Sentiment: Analyst upgrades/targets — Robert W. Baird raised its price target to $257 (outperform) and Wells Fargo raised its target to $215 (equal weight), signaling some sell-side confidence in upside from current levels. Benzinga – Analyst Price Target Changes
• Neutral Sentiment: Full-year revenue guidance roughly in line with consensus — Management issued FY2026 revenue guidance (roughly $2.6B–$2.7B), which appears consistent with street expectations and reduces upside surprise potential from guidance alone. (See Q4 release for guidance details.) Natera Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Analyst consensus — Aggregated analyst coverage remains constructive (average “Moderate Buy”), which supports medium-term expectations but doesn’t preclude short-term volatility. Analyst Average Rating
• Negative Sentiment: Valuation and fundamentals concerns — Despite the beat, Natera still shows negative net margin and negative return on equity on a GAAP basis; combined with a high market capitalization and a recent run-up toward 52-week highs, investors may be taking profits. MarketBeat Q4 Coverage
• Negative Sentiment: Heavy intraday volume and selling pressure — Trading volume was well above average, consistent with a distribution day where some holders trimmed positions after the company’s strong quarter; that drove the stock lower despite the positives. (See intraday volume and price action for context.)

Wall Street Analyst Weigh In

NTRA has been the subject of several analyst reports. Evercore increased their price target on shares of Natera from $190.00 to $250.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Citigroup started coverage on shares of Natera in a research note on Wednesday, January 7th. They set a “buy” rating and a $300.00 price objective for the company. UBS Group increased their target price on shares of Natera from $218.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Piper Sandler lifted their price target on shares of Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Finally, BTIG Research upped their price target on Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $254.47.

Natera Trading Down 3.7%

Shares of Natera stock opened at $208.04 on Friday. The firm’s 50 day simple moving average is $226.52 and its two-hundred day simple moving average is $203.54. The firm has a market capitalization of $28.78 billion, a price-to-earnings ratio of -135.97 and a beta of 1.64. Natera, Inc. has a 12-month low of $125.38 and a 12-month high of $256.36.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. Natera had a negative net margin of 9.03% and a negative return on equity of 16.71%. The firm had revenue of $665.50 million for the quarter, compared to analyst estimates of $600.68 million. During the same period in the previous year, the company earned ($0.41) earnings per share. On average, sell-side analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Insider Transactions at Natera

In other news, insider Solomon Moshkevich sold 1,639 shares of the stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $230.77, for a total value of $378,232.03. Following the transaction, the insider directly owned 137,847 shares of the company’s stock, valued at approximately $31,810,952.19. This represents a 1.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Steven Leonard Chapman sold 4,725 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $230.77, for a total value of $1,090,388.25. Following the completion of the transaction, the chief executive officer owned 123,156 shares of the company’s stock, valued at approximately $28,420,710.12. The trade was a 3.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 368,119 shares of company stock worth $85,956,782 in the last 90 days. 5.63% of the stock is owned by company insiders.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.